AIDS Treatment News logo      

February 16, 2010

SWITCHMRK — Raltegravir Is Not for Everyone!

"An exploratory analysis in this study suggested that a history of ART failure prior to study entry was associated with increased risk of virologic failure among patients who switched to raltegravir, perhaps a consequence of resistance to the nucleoside components of the treatment regimen. The apparent diminished genetic barrier to resistance for raltegravir compared with lopinavir/r then manifested itself with higher rates of virologic failure in this group after the switch. Clinicians should carefully assess all available information — including prior treatment history and results of resistance testing — before modifying successful antiretroviral regimens."

Read more in Journal Watch HIV/AIDS Clinical Care, February 12, 2010.